X4 Pharmaceuticals
XFOR | NASDAQ
$2.83
-$0.29 (-9.29%)
At close: Nov 16, 2026, 4:00 PM ET
$2.84
+$0.01 (+0.35%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-9.29%
(1D)No price chart data available for 1D timeframe.
Rating
47.2
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #345/1021 (Top 34%)
Key Statistics
Market Data
Market Cap $358.06M
1D Range
2.82 3.13
52W Range
2.45 4.67
Valuation (TTM)
PE -4.22
PB 2.58
EV/EBITDA -2.36
Valuation (NTM)
Forward PE N/A
Forward PEG 0.07
Price Target $11.50
Cash Flow
FCF Yield -21.3%
SBC Adj. FCF Yield -24.4%
SBC Impact -14.8%
Margins
Gross Margin 81.6%
Operating Margin -473.9%
FCF Margin -448.7%
Growth (CAGR)
Revenue 3Y | 5Y 45.6% |
65.2%
Dil EPS 3Y | 5Y 21.3% |
74.5%
FCF 3Y | 5Y 24.3% |
-1.7%
Returns
ROA -34.7%
ROE -49.6%
ROIC -37.0%
Financial Health
Net Cash
$187.51M
Current Ratio 13.22
Interest Coverage -9.26
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candi...
Sector Healthcare
Industry Biotechnology
Employees 45
IPO Date Nov 16, 2017
Website www.x4pharma.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 4, 2026
EPS
-$0.16
Beat +4.76%
YoY:
+76.81% REV
$2.9M
Beat +13.28%
YoY:
+64.31%Next Earnings
Mar 16, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$11.50
Upside
+306.36%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove XFOR